Antonio Pardo, MD

Director, Clinical Development
Tris Pharma, Inc.
Monmouth Junction, New Jersey

Presentation(s):

• Poster Number-21 - Cebranopadol, a Novel Potent Analgesic: Pooled Analysis of Clinical Opiate Withdrawal Scales

  Poster Abstracts

• Poster Number-20 - Cebranopadol, a Novel Potent Analgesic: Review of Clinical Studies Conducted Across Multiple Types of Pain including Chronic Lower Back Bain, Acute Pain, Diabetic Peripheral Neuropathy, and Cancer Pain

  Poster Abstracts